Dynamix is a venture-backed drug discovery and development company focused on cancer and autoimmune disorders. The company’s platform technology, DynamixFit™, is uniquely suitable for discovering novel small-molecule Type II kinase inhibitors that carry the promise of better clinical profiles. Dynamix has created a pipeline of proprietary novel products, and expects to start clinical development in 2011